Departments of Oncology-Pathology, Head and Neck Surgery, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Anticancer Res. 2013 Apr;33(4):1575-83.
Human papillomavirus (HPV) is a risk factor for tonsillar squamous cell carcinoma (TSCC) and the presence of HPV is correlated to a better clinical outcome. To find additional biomarkers that, together with HPV, predict clinical outcome, the aim of the present study was to evaluate epidermal growth factor receptor (EGFR) and phosphorylated EGFR (pEGFR) in relation to HPV status and clinical outcome.
A total of 83 pre-treatment TSCC biopsies were analyzed for EGFR and pEGFR Tyr1068 and Tyr1148 by immunohistochemistry, and the obtained data were tested for correlation to tumor HPV status and disease-free survival.
The presence of pEGFR Tyr1068 and 1148, both correlated significantly to the absence of HPV. However, neither of these, nor total EGFR, correlated significantly to disease-free survival for HPV-positive or HPV-negative TSCC.
Since pEGFR Tyr1068 and 1148 are correlated to absence of HPV but not to clinical outcome, these may not be optimal prognostic markers for clinical outcome in patients with TSCC.
人乳头瘤病毒(HPV)是扁桃体鳞状细胞癌(TSCC)的一个风险因素,HPV 的存在与更好的临床结果相关。为了寻找与 HPV 一起预测临床结果的其他生物标志物,本研究旨在评估表皮生长因子受体(EGFR)和磷酸化 EGFR(pEGFR)与 HPV 状态和临床结果的关系。
通过免疫组织化学分析了 83 例 TSCC 活检标本的 EGFR 和 pEGFR Tyr1068 和 Tyr1148,并对获得的数据进行了检测,以评估其与肿瘤 HPV 状态和无病生存率的相关性。
pEGFR Tyr1068 和 Tyr1148 的存在与 HPV 缺失显著相关,但无论是 HPV 阳性还是 HPV 阴性的 TSCC,这两种蛋白都与无病生存率无显著相关性,也与总 EGFR 无显著相关性。
由于 pEGFR Tyr1068 和 Tyr1148 与 HPV 缺失相关,但与临床结果无关,因此它们可能不是 TSCC 患者临床结果的最佳预后标志物。